GBL-Memory1
An exciting opportunity exists to acquire the assets related to GBL-Memory1 – a clinically validated, patented nutraceutical complex developed by plant biotechnology innovator Green Bioactives Limited - in Provisional Liquidation (“Green Bioactives” or the “Company”). GBL-Memory1 has demonstrated a 10.1% improvement in total memory in a peer-reviewed human clinical study and is already in-market across the UK, EU, and other global territories.
The Company has invested substantially in R&D and IP protection, and has existing supply, distribution and manufacturing relationships in place to support commercial scaling. The estimated development cost for the GBL-Memory1 platform is in excess of £5 million.
Deadline for best and final offers is set for 5pm on 17 July 2025. Requests for further information should be addressed to Emily Muir or Molly Greenhow of SIA Group who are acting as agents.
are registered trademarks of SIA Group Asset Ingenuity Limited